210 related articles for article (PubMed ID: 27108935)
41. Recent developments in 5-HT3 receptor pharmacology.
Thompson AJ
Trends Pharmacol Sci; 2013 Feb; 34(2):100-9. PubMed ID: 23380247
[TBL] [Abstract][Full Text] [Related]
42. The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro.
Wong EH; Clark R; Leung E; Loury D; Bonhaus DW; Jakeman L; Parnes H; Whiting RL; Eglen RM
Br J Pharmacol; 1995 Feb; 114(4):851-9. PubMed ID: 7773546
[TBL] [Abstract][Full Text] [Related]
43. Molecular mechanisms of 5-HT(3) and NK(1) receptor antagonists in prevention of emesis.
Rojas C; Raje M; Tsukamoto T; Slusher BS
Eur J Pharmacol; 2014 Jan; 722():26-37. PubMed ID: 24184669
[TBL] [Abstract][Full Text] [Related]
44. Therapeutics of 5-HT3 receptor antagonists: current uses and future directions.
Machu TK
Pharmacol Ther; 2011 Jun; 130(3):338-47. PubMed ID: 21356241
[TBL] [Abstract][Full Text] [Related]
45. Mode of antagonism of methoctramine, AF-DX 116 and hexahydrosiladifenidol in guinea-pig left atrium and ileum: comparison of Schild and resultant analysis.
Boselli C; Grana E
J Auton Pharmacol; 1995 Apr; 15(2):115-27. PubMed ID: 7615574
[TBL] [Abstract][Full Text] [Related]
46. The pyrrole etomidate analog carboetomidate potently inhibits human 5-HT3A receptor function: comparisons with etomidate and potential implications for emetogenesis.
Desai R; Miller KW; Raines DE
Anesth Analg; 2013 Mar; 116(3):573-9. PubMed ID: 23400978
[TBL] [Abstract][Full Text] [Related]
47. Design, synthesis and evaluation of antidepressant activity of novel 2-methoxy 1, 8 naphthyridine 3-carboxamides as 5-HT3 receptor antagonists.
Mahesh R; Dhar AK; Jindal A; Bhatt S
Chem Biol Drug Des; 2014 May; 83(5):583-91. PubMed ID: 24330585
[TBL] [Abstract][Full Text] [Related]
48. 5-HT(3) receptors.
Lummis SC
J Biol Chem; 2012 Nov; 287(48):40239-45. PubMed ID: 23038271
[TBL] [Abstract][Full Text] [Related]
49. Ondansetron and granisetron binding orientation in the 5-HT(3) receptor determined by unnatural amino acid mutagenesis.
Duffy NH; Lester HA; Dougherty DA
ACS Chem Biol; 2012 Oct; 7(10):1738-45. PubMed ID: 22873819
[TBL] [Abstract][Full Text] [Related]
50. 5-Chloroindole: a potent allosteric modulator of the 5-HT₃ receptor.
Newman AS; Batis N; Grafton G; Caputo F; Brady CA; Lambert JJ; Peters JA; Gordon J; Brain KL; Powell AD; Barnes NM
Br J Pharmacol; 2013 Jul; 169(6):1228-38. PubMed ID: 23594147
[TBL] [Abstract][Full Text] [Related]
51. Subunit-dependent inhibition and potentiation of 5-HT3 receptor by the anticancer drug, topotecan.
Nakamura Y; Ishida Y; Yamada T; Kondo M; Shimada S
J Neurochem; 2013 Apr; 125(1):7-15. PubMed ID: 23305320
[TBL] [Abstract][Full Text] [Related]
52. The Binding of Palonosetron and Other Antiemetic Drugs to the Serotonin 5-HT3 Receptor.
Zarkadas E; Zhang H; Cai W; Effantin G; Perot J; Neyton J; Chipot C; Schoehn G; Dehez F; Nury H
Structure; 2020 Oct; 28(10):1131-1140.e4. PubMed ID: 32726573
[TBL] [Abstract][Full Text] [Related]
53. Selective blocking effects of tropisetron and atropine on recombinant glycine receptors.
Maksay G; Laube B; Betz H
J Neurochem; 1999 Aug; 73(2):802-6. PubMed ID: 10428078
[TBL] [Abstract][Full Text] [Related]
54. Anticancer drug irinotecan inhibits homomeric 5-HT3A and heteromeric 5-HT3AB receptor responses.
Nakamura Y; Ishida Y; Yamada T; Shimada S
Biochem Biophys Res Commun; 2011 Nov; 415(2):416-20. PubMed ID: 22044840
[TBL] [Abstract][Full Text] [Related]
55. The 5-HT3 receptor as a therapeutic target.
Thompson AJ; Lummis SC
Expert Opin Ther Targets; 2007 Apr; 11(4):527-40. PubMed ID: 17373882
[TBL] [Abstract][Full Text] [Related]
56. SR 57227A is a partial agonist/partial antagonist of 5-HT
Nakamura Y; Kondo M; Koyama Y; Shimada S
Biochem Biophys Res Commun; 2019 Jan; 508(2):590-596. PubMed ID: 30509492
[TBL] [Abstract][Full Text] [Related]
57. 5-HT3 and 5-HT4 receptors and cholinergic and tachykininergic neurotransmission in the guinea-pig proximal colon.
Briejer MR; Schuurkes JA
Eur J Pharmacol; 1996 Jul; 308(2):173-80. PubMed ID: 8840129
[TBL] [Abstract][Full Text] [Related]
58. Varenicline Interactions at the 5-HT3 Receptor Ligand Binding Site are Revealed by 5-HTBP.
Price KL; Lillestol RK; Ulens C; Lummis SC
ACS Chem Neurosci; 2015 Jul; 6(7):1151-7. PubMed ID: 25648658
[TBL] [Abstract][Full Text] [Related]
59. RS 23597-190: a potent and selective 5-HT4 receptor antagonist.
Eglen RM; Bley K; Bonhaus DW; Clark RD; Hegde SS; Johnson LG; Leung E; Wong EH
Br J Pharmacol; 1993 Sep; 110(1):119-26. PubMed ID: 8220871
[TBL] [Abstract][Full Text] [Related]
60. Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
Del Cadia M; De Rienzo F; Weston DA; Thompson AJ; Menziani MC; Lummis SC
Bioorg Med Chem; 2013 Dec; 21(23):7523-8. PubMed ID: 24128813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
